Intelligent Bio Solutions (Nasdaq: INBS) completes key precision tests for U.S. drug screen
Rhea-AI Filing Summary
Intelligent Bio Solutions Inc. reported completing extensive precision testing to support its planned FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine.
The precision program covered more than 1,600 tests across three production runs and three independent sites, demonstrating repeatable, reproducible performance suited to workplace and other drug screening environments. These data, together with penetration testing and prior Cut-off, Method Comparison, and Interference Studies, form a comprehensive package addressing safety, accuracy, usability, specificity, security, and precision. The company describes the U.S. drug screening market as a multi‑billion‑dollar annual opportunity and highlights rapid, non‑invasive fingerprint testing with results in under ten minutes.
Positive
- None.
Negative
- None.
Filing Explained
Intelligent Bio Solutions reports completed precision testing, with the results intended for a planned FDA 510(k) submission; the disclosed change is a more complete submission package, while the U.S. launch remains a future step tied to obtaining clearance.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Precision tests completed: more than 1,600 tests
Production runs covered: three production runs
Independent testing sites: three independent sites
+2 more
5 metrics
Precision tests completed
more than 1,600 tests
Precision testing of the Intelligent Fingerprinting Drug Screening System for codeine detection
Production runs covered
three production runs
Manufacturing conditions assessed during precision testing
Independent testing sites
three independent sites
Operating environments used in the precision testing program
U.S. drug screening market size
multi-billion-dollar annual opportunity
Company’s description of potential U.S. market served by its system
Result time
under ten minutes
Time for the Intelligent Fingerprinting Drug Screening System to deliver results
Key Terms
FDA 510(k) submission, Intelligent Fingerprinting Drug Screening System, precision testing, Cut-off Study, +1 more
5 terms
FDA 510(k) submission regulatory
"a key component of the Company’s FDA 510(k) submission for U.S. market clearance"
An FDA 510(k) submission is a regulatory filing to show a new medical device is sufficiently similar to an already-approved device so it can be marketed in the U.S. without undergoing the most extensive premarket review. For investors, 510(k) clearance is a key milestone that reduces regulatory uncertainty and shortens time to sales—think of it as proving a new product is close enough to an established model to be sold without rebuilding trust from scratch.
Intelligent Fingerprinting Drug Screening System technical
"U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine"
precision testing medical
"The precision testing included more than 1,600 tests across three production runs"
Cut-off Study medical
"data collected from the previously announced Cut-off Study, Method Comparison Study"
Interference Study medical
"Method Comparison Study, and Interference Study"
An interference study tests whether other substances or conditions prevent a medical test, drug measurement, or diagnostic device from working properly, like checking if a smartphone case blocks charging. Investors should care because interference problems can limit a product’s accuracy, regulatory approval, market acceptance, or lead to costly redesigns and lost sales, so clear results reduce risk and support commercial reliability.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Intelligent Bio Solutions (INBS) announce on July 21, 2026?
Intelligent Bio Solutions announced completion of precision testing supporting its planned FDA 510(k) submission for U.S. clearance of its Intelligent Fingerprinting Drug Screening System to detect the opiate codeine. The extensive testing underpins a future planned U.S. launch, subject to obtaining regulatory clearance.
How extensive was the precision testing described by INBS?
The company completed more than 1,600 tests across three production runs and three independent sites. Results showed repeatable, reproducible performance under varied manufacturing conditions and operating environments, supporting suitability for workplace and other drug screening settings once regulatory clearance is obtained.
What role does the precision testing play in INBS’s FDA 510(k) submission?
The precision testing is a key component of INBS’s FDA 510(k) submission package for its codeine fingerprint drug screening system. It will be included alongside penetration testing and data from Cut-off, Method Comparison, and Interference Studies to address safety, accuracy, and other performance criteria.
What market opportunity does INBS see for its drug screening system?
INBS describes the U.S. drug screening market as a multi-billion-dollar annual opportunity. Potential applications include workplace testing, criminal justice, pain management, and substance abuse treatment, where its non-invasive fingerprint technology aims to provide rapid results and flexible on-site screening.
What advantages does INBS’s Intelligent Fingerprinting Drug Screening System offer?
The system uses non-invasive fingerprint sweat analysis to screen for recent drug use, including opiates, cocaine, methamphetamine, and cannabis. Sample collection takes seconds and results are available in under ten minutes, which can help employers and other users conduct convenient, hygienic, on-site testing.